Paclitaxel Accord (Paclitaxel)

Paclitaxel is employed in oncology to interfere ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

• Breast cancer: improves disease‑free survival when combined with other agents.
• Non‑small cell lung cancer: used as a first‑line or second‑line therapy in combination regimens.
• Ovarian cancer: administered after surgical debulking to reduce recurrence risk.
• Kaposi's sarcoma: provides antitumour activity in HIV‑related disease.
• Gastric cancer: part of combination protocols for advanced disease.
• Pancreatic cancer: used in multi‑drug regimens for metastatic disease.

• Paclitaxel stabilises microtubules by binding to the β‑tubulin subunit, preventing depolymerisation during cell division. This blockade arrests cells in the G2/M phase of the mitotic cycle, leading to apoptosis of rapidly proliferating cancer cells. The drug’s action is independent of the tumour’s hormonal status and is not reliant on DNA synthesis pathways.

Paclitaxel may elicit a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count increasing infection risk.
• Alopecia: hair loss that may be temporary.
• Peripheral neuropathy: tingling or numbness in extremities.
• Nausea and vomiting: gastrointestinal upset.
• Fatigue: generalised tiredness.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Anaphylactic reactions: severe hypersensitivity requiring immediate medical attention.
• Cardiotoxicity: arrhythmias or decreased cardiac function.
• Severe neutropenic infection: febrile neutropenia.
• Pulmonary toxicity: interstitial pneumonitis.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Thromboembolic events: deep vein thrombosis or pulmonary embolism.

When administering  ​  ​  ​   ​  ​  ​  ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​

• Assess  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​  ​ ​: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​
• Monitor ​ ​  ... (the rest of the content has been truncated)

• The   ​  ...